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Abstract
The Consultation on a Strategy for Services for COPD in England is the culmination of five years’ work by respiratory specialists from all
disciplines, as well as representatives from the voluntary sector, patients, carers and planners. It has been led by the Department of Health
in England and the joint National Directors for the programme, Professor Sue Hill and Dr Robert Winter. The Strategy outlines service
standards for providers of COPD care and is complementary to the UK National Institute for Health and Clinical Excellence (NICE)
guidelines on the management of COPD. Its key elements are:
• preventing the development and progression of COPD
• diagnosing COPD accurately and at an early stage
• developing structured care based on national guidance
• promoting self-management education
• reducing the number of people admitted to hospital
• improving access to end-of-life care 
• promoting good asthma services.
In essence this is an aspirational strategy which aims to change the way that the NHS in England delivers care for people with COPD by
identifying them earlier and managing them optimally in order to reduce the likelihood of progression to the more severe stages of the
disease. An economic impact assessment shows that implementing the Strategy will save approximately £1billion over 10 years as well
as sparing many people from a debilitating illness. 
This supplement is based on the Strategy Consultation document as well as the NICE guidelines for COPD management. It aims to
elucidate practical implementation of the COPD Strategy, and includes verbatim the Strategy recommendations as well as highly relevant
clinical information from the NICE guidelines. Implementation of the Strategy recommendations should lead to optimum care for patients
with COPD. 
© 2010 Primary Care Respiratory Society UK. All rights reserved.
R Jones et al. Prim Care Resp J 2010;19(Suppl 2): S1-S17 
doi:10.4104/pcrj.2010.00081
Keywords: COPD, Strategy, services, England, Department of Health, prevention, diagnosis, case-finding, treatment, 
chronic care, self-management, exacerbations, end-of-life care, implementation  
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Introduction
Steve Holmes
Chronic obstructive pulmonary disease (COPD) is currently the sixth
largest cause of death worldwide and is anticipated to be the third
commonest cause of death by 2020.1 It is also the second commonest
reason for emergency hospital admission in the UK, accounting for
27,000 admissions per year.2 There is now increased awareness of
significant numbers of undiagnosed patients,3 and of the wide
variation in the quality of care provided.1,4,5 COPD-related healthcare
costs are a significant proportion of any country’s economy,4 and cost
effective use of resources is now increasingly important.6
Following a report from England’s Chief Medical Officer in
2005,7 the Department of Health (DOH) in England has been
developing a National Strategy to enhance the care of patients with
COPD. This has required a structured process using expertise from
many areas of the respiratory community – emphasising the
importance of transcending traditional primary/secondary care
boundaries – and the UK Primary Care Respiratory Society (PCRS-UK)
has been involved throughout.8
The Consultation on a Strategy for Services for COPD in England
has now been published.9 This will clearly need to link with other
national policy, and a UK government White Paper published in July
2010 is anticipated to have far-reaching consequences on the
structure and methods of commissioning of services within the UK
National Health Service (NHS).10 The Consultation document9 also
links with the recently published 2010 update on COPD
management from the UK National Institute for Health and Clinical
Effectiveness (NICE).11
This article covers the key areas identified in the Consultation
document;
• prevention, awareness and identification of COPD 
• diagnosis and differentiation from asthma and other respiratory
diseases
• high quality acute and chronic care
• self-management 
• end-of-life care
• implementation 
The importance of smoking cessation7,12-14 is emphasised, as is
the fact that more needs to be done to inform the population about
COPD and its implications.3 The presence of “missing millions” with
undiagnosed COPD requires improved case-finding and possibly
screening,15,16 as well as quality diagnostic spirometry to complement
clinical assessment.8,17-21 There is a gap between ideal and provided
care, and wide variation in provision across all areas of the health
service,21 which the Strategy attempts to address. Finally, there is
emphasis on the importance of end-of-life care for patients with
COPD.
Implementation of the Strategy for COPD services in England
across all areas of the health service will be crucial, and the
publication of this PCRJ supplement, following publication of the
Consultation document,9 is part of the implementation process. The
24 Key Recommendations of the Strategy are highlighted
throughout the text. In order to increase relevance to practising
clinicians, where appropriate there is clinical content based largely
on the 2010 NICE guideline.11 The PCRS-UK has also published an
online Quick Reference Guide22 summarising the Strategy
Consultation document.
The Strategy for COPD services in England has widespread
applicability. If the Strategy achieves its aims, it should stimulate
improved quality of care for COPD patients for many years to come.
Prevention and awareness
Rupert Jones
Recommendation 1: Work should be undertaken locally to
identify where prevalence is high, and planned interventions
should be developed to encourage behaviour change and
help to minimise inequalities.
The stark statistics in the Consultation on a Strategy for
COPD Services in England9 show that COPD affects 2.8 million
people with only 0.8m diagnosed. COPD costs the UK NHS £1
billion, it causes 1 in 8 emergency admissions, 30% are
readmitted soon after, and it accounts for at least 5% of all
deaths in England and Wales (24,800 in 2008) and is a
contributor to many more. The burden is growing, especially in
women; more women die of COPD than from breast cancer.23
COPD is more common in lower socio-economic groups and
interacts with other conditions – for example, for every 10%
decrease in FEV1, cardiovascular events and deaths increase by
20% and 28%, respectively.24
Notwithstanding this, 89% of the UK population have not
heard of COPD. The Strategy aims to raise awareness in the
population and emphasise the causes of COPD and the fact that
COPD is both treatable and preventable. 
PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
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Recommendation 2: The importance of lung health should
be understood and people should take appropriate action to
maintain good lung health.
Prevention policies need to start in pregnancy, through
childhood and onwards (see Figure 1). There is potential to
prevent COPD by people adopting healthy lung behaviours such
as avoiding cigarette smoke, occupational and other harmful
exposures. Many people develop major lung damage without
symptoms and this group may be difficult to identify. Others do
have symptoms without seeking help – they may have
breathlessness on exertion which they attribute to ageing, and a
cough which they attribute to smoking. These people, who are
at risk of COPD, need to be encouraged to seek an assessment
of their lungs. This can be done by proactive means (case-finding)
or opportunistically (using existing healthcare interventions such
as smoking cessation programmes).
Recommendation 3: The consequences of exposure to the
main risk factors of COPD should be understood and people
with early symptoms of lung disease need to be able to
recognise their symptoms and seek further investigation.
The roots of the disease start in utero and in childhood, when
factors such as atopy, passive smoking and respiratory infections
may be as important as conventional risk factors such as
smoking.25 There is a strong relationship between lifelong
cigarette exposure in pack years and the chance of developing
COPD.26 Approximately half of those with COPD are current
smokers, and these patients report that 8% have not been told
to stop and a third have not been offered treatment or referral to
smoking cessation clinics.27 Effective therapies exist especially
when part of a structured smoking cessation programme
supported by medication – for example, varenicline improves quit
rates fourfold in people with COPD.28
Recommendation 4: Further evaluation work should be
undertaken on the impact of the use of lung age tests on
individuals’ motivation for smoking cessation and testing for
lung disease as a case-finding approach.
The Strategy External Reference Group recommended
consideration of a lung health check in children and young adults
at ages 7 and 14, and in adults at ages 25 and 40 years.8 In
adults, increased use of case-finding spirometry and
questionnaires may promote earlier detection of COPD.16
Such screening and case-finding programmes will have
significant resource implications, and will therefore be tested by
the National Screening Committee and also, where appropriate,
in primary care pilots to assess feasibility, efficacy and cost
benefit. The aim is to:
• test lung function in these age groups and identify those at risk
of future problems
• ask about respiratory symptoms and take necessary steps
• identify risk factors and educate to change future risks.
Recommendation 5: Employers should look to minimise
the risks of workforce exposure to known risk factors and
work with partners from health and social care to support
people with COPD to manage their condition and remain in
work.
The Consultation document specifically aims to raise
awareness of symptoms for those at risk, and to encourage
individuals to adopt strategies to prevent or ameliorate future
health problems.9 By promoting the concept of lung health and
symptomatology, the Strategy should provide an opportunity to
identify COPD earlier. 
Identification and diagnosis
Rupert Jones and Judith Lawrence
Fundamental to the Consultation on a Strategy for Services for
COPD in England is the early identification and diagnosis of those
individuals at risk. Its success will be influenced by the ability of
health care professionals to collaborate with other care providers
to meet the needs of the patient. 
Focusing on identification and diagnosis, the Consultation
document9 proposes several key areas for targeting resources:
• Early identification
• Accurate quality-assured diagnosis 
• Spirometry assessment in COPD
• Disease Registers
• Information
There needs to be a multifaceted approach to identification
and diagnosis:
• People need to be aware of the symptoms of lung disease and
when to seek assessment and advice from health care
professionals
PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
Individual Life Journey
Low Risk High Risk
(Future)
High Risk
(Current)
Lung Disease
(COPD) / Lung Age
Lung Health
M
E
S
S
A
G
E
S
People who
are well
Desired response:
‘My lungs are
clean and healthy,
and I want to keep
them that way.’
People who do not
have symptoms
Desired response:
‘My lungs may be
damaged, but I
don’t want it to get
any worse.’
People who
have symptoms
Desired response:
‘I might have a
problem, but
there’s something
I can do about it.’
People who have
been diagnosed
with COPD
Desired response:
‘I have COPD
and I know how
to manage
my illness.’
Prevention Earlyidentification
High
Quality Care
Figure 1.  Individual life journey. Reproduced with
permission from the Department of Health 2010.9
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• Health care professionals must be competent in the assessment
and diagnosis of COPD, a fundamental ability being the ability
to take an accurate history. 
• Health care professionals must be able to differentiate between
COPD and other respiratory diseases such as asthma to ensure
that the patient is offered optimum care (see Figure 2).
Recommendation 23: The NHS should recognise
similarities and differences between asthma and COPD, and
should commission services accordingly to optimise the
model of provision of care
Recommendation 10: Disease registers should be accurate
and used to improve COPD outcomes.
• Competent assessment of disease severity should be based on a
number of features, not just one entity or test, to ascertain
disability and prognosis.
• Disease registers must be accurate and up to date to ensure
regular review of diagnosed patients, managing care and
targeting resources. 
• Quality information obtained at assessment must be recorded
accurately
Recommendation 6: Healthcare professionals should
understand the risk factors for COPD and offer advice or an
appropriate intervention to those who are at risk.
Health care professionals should understand the risk factors
for COPD and be able to identify those at risk (see Table 1), offer
them appropriate education to prevent the disease developing,
and assess patients’ lungs to establish the presence of lung
disease and its cause. 
While COPD presents in adults, failure of adequate lung
development or damage in childhood reduces pulmonary
reserves and puts individuals at an increased risk of developing
symptomatic lung disease later in life.25 In adults, lung damage
occurs without symptoms, so warning people of the causes of
lung disease allows them to change their lifestyle before
permanent serious damage accrues. By the time someone is
breathless with COPD, much irreversible damage is done and the
lungs will only get worse with time.
There is insufficient evidence, as yet, for widespread
screening, and the case for lung health checks in children and
adults aged 25 and 408 is being assessed in research projects.
However, it may be useful to consider the risks throughout
people’s lives so they can be made aware of positive steps to take
to keep their lungs healthy.
Target groups for COPD identification
In practice, widespread screening in asymptomatic people is not yet
required. Screening or case-identification of at-risk groups can be
performed using symptom-based questionnaires29,30 or the
measurement of airflow obstruction such as case-finding spirometry.
Practices should be prepared to check people in the following
groups: 
First priority
Smokers over the age of 40 with:
• >20 pack-year smoking history
PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
Figure 2.  Differentiating asthma from COPD. Reproduced with permission from the National Institute of Health and
Clinical Excellence.11
Risk factors that affect children 
• Alpha-1-antitrypsin deficiency
• Smoking in pregnancy
• Low birth weight
• Severe viral and other infections in infancy 
• Asthma and wheezing in childhood
• Environmental pollution (including cigarette smoke)
• Smoking in childhood 
• Childhood deprivation, poor nutrition including obesity
Risk factors for adults 
• Smoking
• Occupation
• Environment and family history
• Health events in childhood
• Genetic susceptibility
Table 1. Risk factors for developing COPD.
Clinical features differentiating COPD and asthma COPD Asthma
Smoker or ex-smoker Nearly all Possibly
Symptoms under age 35 Rare Often
Chronic productive cough Common Uncommon
Breathlessness Persistent and progressive Variable
Night time waking with breathlessness and/or wheeze Uncommon Common
Significant diurnal or day to day variability of symptoms Uncommon Common
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• Frequent courses of antibiotics and/or inhaled medication
• Chronic cough
• Breathlessness
• On existing asthma registers 
Then: All smokers over the age of 40
Then: Individuals over the age of 40 and any of the following
characteristics:
• Ex-smoker
• Previous pulmonary tuberculosis
• First-degree relative of those with COPD
• Known occupational or environmental exposure (coal mining,
exposure to wood burning stoves)
Once identified, the risk factors and symptoms should be
documented and spirometry performed with other tests as
appropriate to diagnose the underlying lung condition(s).
Whilst the Consultation document recommends assessing
patients over 40,9 NICE suggests a lower limit of age 35 and
above.11
Diagnosing COPD  
Recommendation 8: A diagnosis of COPD should be
confirmed by quality assured spirometry and other
investigations appropriate to the individual.
The definition of COPD in the Consultation on a Strategy for
Services for COPD in England9 follows the recommendations from
GOLD31 and the 2010 NICE revision.11 The diagnosis requires high
quality post-bronchodilator spirometry combined with clinical
assessment and exclusion of other diagnoses. Currently, the
standards of spirometry performance and interpretation are a cause
for concern throughout primary care, and to a lesser extent in
secondary care.15,17 Furthermore, audit data suggest that 27% of
those on COPD registers do not meet the diagnostic criteria for
COPD, while failure to use post-bronchodilator spirometry may
result in severity being overestimated in 18%.32
A diagnostic algorithm is shown in Figure 3.
Problems identified with providing accurate spirometry include:17
• Inappropriate equipment
• Lack of calibration
• Inadequate training on conduct and quality checks
• Inadequate support 
• Problems interpreting the result
The Strategy requires that quality-assured diagnostic standard
spirometry is required to make the diagnosis of COPD and assess
disease severity, and the current recommendations17 include the
following: 
The spirometer:
• should be able to record the parameters of forced expiratory
volume in one second (FEV1), forced vital capacity (FVC), the
FEV1/FVC ratio, and display a graph of volume against time. 
• should be calibrated before use
The spirometrist should be trained:
• in its use and calibration
• in how to spot faults such as slow start, extra breaths etc.
• to understand the preparation of the patient for various types of
spirometric assessment 
• to understand which readings are required in different clinical
scenarios such as reversibility testing or when to use the  slow
vital capacity
Whoever interprets the spirometry results to make the
diagnosis must be able to calculate the following (see Table 2):
• FEV1
• FVC
• FEV1 %  predicted 
• the ratio of FEV1 to VC (highest of FVC or SVC)
Anyone performing diagnostic standard spirometry should
undertake quality-assessed, certified and approved training. With
regard to case-finding spirometry, any form of spirometry not
meeting diagnostic standards as outlined above should be
considered as “case-finding”.18 Case-finding spirometry may be
performed using hand-held or screening devices used for
detecting airflow obstruction, though the Strategy Consultation
document has recommended further research.
For post-bronchodilator readings it is not necessary to stop
treatment prior to the test. Post-bronchodilator tests are needed
for the diagnosis in the majority of cases and for monitoring
PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
Figure 3.  COPD diagnostic algorithm (adapted from NICE
with permission11).
Think of the diagnosis of
COPD for patients who are: 
• over 35
• smokers or ex-smokers
• and have any of these
symptoms:
◗ exertional breathlessness
◗ chronic cough
◗ regular sputum production
◗ frequent winter ‘bronchitis’
◗ wheeze
• and have no clinical features
of asthma (see table below)
If in doubt,
consider the following pointers:
Asthma may be present if:
• serial peak flows show significant variability
• 400 ml response to bronchodilators
• 400 ml response to 30mg
prednisolone daily for 2 weeks
COPD is not present if FEV1 and FEV1/FVC ratio
return to normal with drug therapy
Consider further investigatons
Reassess diagnosis in view of response to treatment
Perform spirometry if COPD
seems likely
Airflow obstruction is defined
as post-bronchodilator
FEV1/FVC <0.7
Spirometric reversibility
testing is not usually
necessary as part of the
diagnostic process or to plan
initial therapy
If still in doubt, make a
provisional diagnosis and
start empIrIcal treatment
If no doubt, diagnose
COPD and start
treatment
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people with diagnosed COPD. 
For reversibility testing drugs have to be stopped well in
advance. Reversibility testing is needed in a minority of cases to
differentiate the causes of airflow obstruction – e.g.
differentiating asthma from COPD.11
Establishing a spirometry service is key to achieving the aims
of the Strategy. The Consultation document does not define who
should do spirometry or where it should be done, but does
require the person to have the right competencies.9 A variety of
models include a ‘hub and spoke’ system whereby a team of
experts in the centre (or ‘hub’) is able to train, assess and support
those performing spirometry in practice (the ‘spokes’), and these
various models are being tested as part of the work being
undertaken with NHS Improvement.
Assessment of severity in COPD
Recommendation 9: An assessment of the severity and
presence of co-morbid conditions should be made at the
point of initial diagnosis, and at least every three years.
No single measure can assess the severity of COPD accurately.11 For
this reason, healthcare professionals should use a variety of
prognostic indicators in order to guide practice and plan
appropriate care. Disability and FEV1 do not always correlate, and
therefore FEV1 should not be used in isolation. The following
prognostic factors should be used to formulate a more holistic
view of the patient’s overall wellbeing:
• FEV1
• Breathlessness (MRC scale)
• Health status
• Exercise capacity (6-minute walk test)
• BMI
• Presence of cor pulmonale
• Presence of respiratory failure using pulse oximetry or arterial
blood gas analysis
• Carbon monoxide transfer factor (TLCO)
• Presence of co-morbidities
NICE11 recommends using the BODE index,33 [Body Mass
Index, Degree of Airflow Obstruction expressed as FEV1%
predicted, Dyspnoea (MRC Dyspnoea score), and Exercise
indicator limitation (6-minute walking test)], a multidimensional
grading system. The BODE index is better than the FEV1 at
predicting the risk of death from any cause and from respiratory
causes among patients with COPD.11 However, a 6-minute
walking test is required which can be difficult to undertake in
primary care. More recently validated alternatives are the DOSE34
(Dyspnoea, Airways Obstruction, Smoking Status, Exacerbation)
and ADO35 indexes. However, there was insufficient evidence yet
for these to be recommended by NICE.11
The 2010 NICE guideline11 on severity classification of airflow
obstruction (which should not be equated with ‘disease’ severity) is
in line with the recommendations by GOLD31 and the ATS/ERS37 (see
Table 2). NICE suggests that asymptomatic patients with GOLD
stage 1 (FEV1 >80% and FEV1/FVC ratio <0.7) should not be
considered as suffering respiratory disease, but symptomatic
patients with GOLD stage 1 have worse health status, and higher
rates of FEV1 decline and health care consumption.38
Confirming the diagnosis
There is no single test to diagnose COPD. Once diagnostic
standard post-bronchodilator spirometry has confirmed airflow
obstruction, the diagnosis should be confirmed by;
(i) excluding other causes – e.g. bronchiectasis or tumour, and 
(ii) establishing that the patient has appropriate clinical features. 
A full description of the clinical features of COPD and related
respiratory illness such as asthma are outside the remit of this paper,
but details are summarised in the NICE COPD guideline (see Table
3)11 and national39 and international40 asthma guidelines.  
Recommendation 7: In line with WHO advice, all people
with a diagnosis of COPD and/or a history of adult asthma
should be assessed for alpha-1-antitrypsin deficiency.
All patients with COPD should have a chest radiograph (CXR).
An alpha-1-antitrypsin blood test is recommended for all COPD
patients by the World Health Organisation and the Consultation
document,9 but NICE 2010 suggests that testing should only occur
if there is early onset, minimal smoking history or a family history.11
Where the diagnosis is in doubt or symptoms are atypical (for
R Jones et al.
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NICE clinical ATS/ERS GOLD NICE clinical guideline
guideline 12 (2004)36 200437 200831 101 (2010)11
Post- FEV1 % 
bronchodilator predicted Severity of airflow obstruction
FEV1/FVC
Post-bronchodilator Post-bronchodilator Post-bronchodilator
< 0.7 > 80% Mild Stage 1 – Mild Stage 1 – Mild*
< 0.7 50–79% Mild Moderate Stage 2 – Moderate Stage 2 – Moderate
< 0.7 30–49% Moderate Severe Stage 3 – Severe Stage 3 – Severe
< 0.7 < 30% Severe Very severe Stage 4 – Very severe** Stage 4 – Very severe**
*Symptoms should be present to diagnose COPD in people with mild airflow obstruction   **Or FEV1 < 50% with respiratory failure.
Table 2. Classification of airflow obstruction severity according to various guidelines.  Reproduced with permission from
the National Institute for Health and Clinical Excellence.11
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example, disproportionate breathlessness) referral for further
investigation may be required. 
Patients with confirmed COPD should be entered on the
disease register and assessed for disease severity including: 
• Lung function (FEV1% predicted)
• Breathlessness (MRC dyspnoea scale)
• Exacerbation frequency
• Smoking status
• Body mass index 
• Important co-morbid conditions
The Strategy Consultation document also suggests recording
a measure of health status – for example, the COPD assessment
test (‘CAT’ – see http://www.catestonline.org).41
COPD management: chronic ongoing care
Kevin Gruffydd-Jones and Rupert Jones
This section of the Strategy Consultation document9 emphasises
moving away from current models of purely reactive management
(such as control of symptoms and  management of acute
exacerbations) towards a system of proactive care involving
minimising the future risk of exacerbations and hospital admissions,
and slowing disease progression.  
Adapting the chronic care model for COPD
The chronic care model of Wagner42 has identified four essential
elements in structured care likely to have a major impact on the
quality, effectiveness and efficiency of care:
• provision of a comprehensive system to support clinical
management
• promotion of self-management and adoption of a healthy
lifestyle
• evidence-based support for decision making
• use of Clinical guidelines.
Recommendation 12: Chronic disease management
approaches should be adopted in health and social care for
all people diagnosed with COPD, irrespective of severity or
symptoms
Clinical Networks
An important factor in the implementation of the Strategy will be
the development of local Clinical Networks bringing together
primary and secondary health care professionals, managers and
patients, to commission, provide and support COPD services in a
locality. These will be supported at Strategic Health Authority (SHA)
level by COPD Clinical leads.
Assessment and Review
One of the key elements of proactive COPD management is proper
assessment at the time of diagnosis followed by regular structured
review.
1. Assessing severity
Traditionally the severity of disease has been linked to the degree of
airflow obstruction. The 2004 NICE Guideline36 criteria for severity of
airflow obstruction has recently been updated11 in line with the
GOLD criteria31 (see Table 2).
However, the degree of airflow obstruction correlates poorly
with quality of life and exercise limitation, and therefore disease
severity should be assessed in conjunction with other patient-
centred markers of disease activity such as dyspnoea scores,
health status, and frequency of exacerbations. 
Multi-dimensional  assessment tools have been developed.
The BODE index33 assesses disease severity by various
measurements and is seen as an evidence-based prognostic
indicator. Other more primary care-friendly indices have been
developed (DOSE34 and ADO35).  
2.  Frequency of review
It is recommended that proactive review be carried out at intervals
according to disease severity. For example, a patient with stable mild
disease (FEV1 70% predicted, MRC score 2, no exacerbations) can
be reviewed annually, whilst a patient with more severe disease
(FEV1 40% predicted, MRC score 4, and more than one
exacerbation per year) might be reviewed 6-monthly and after each
exacerbation (especially after admission).
There is considerable interest in Patient-Reported Outcome
Measures (PROMS) which measure the impact of the disease on the
patient, especially in terms of quality of life. There are several self-
completed questionnaires available which measure this and these
are being piloted by the DOH. There is particular interest in the 8-
question patient-completed COPD assessment test (CAT)41 which
can be completed quickly by patients as part of a COPD review,
providing information on the impact of COPD on their health. 
3. Elements of a regular clinical review 
A patient on the COPD register requires regular clinical review in
order to:
• Assess the impact of the disease upon the patient in terms of
symptoms, functional limitation, quality of life, psychological
and social factors, exacerbations, lung function and
hypoxaemia.
• Promote self-management by education, health promotion
(including giving up smoking) and use of individualised action
plans where appropriate.
• Review the need for, efficacy of, and safety of, pharmacological
and non-pharmacological interventions (including inhaler
technique)
PRIMARY CARE RESPIRATORY JOURNAL
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Symptoms Signs
Exertional breathlessness Hyperinflated chest
Chronic cough Wheeze or quiet breath sounds
Regular sputum production Purse lip breathing
Frequent winter “bronchitis” Use of accessory muscles
Wheeze Paradoxical movement of lower ribs
Exertional breathlessness Reduced crico-sternal distance
Table 3. Clinical Features of COPD (adapted from NICE
with permission11).
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• Identify co-morbid conditions and the emergence of
complicating associated conditions such as lung cancer or
bronchiectasis
• Consider the need for specialist respiratory referral including
oxygen assessment and palliative care
Figure 4 shows an example of a COPD review template used in
a primary care setting (including Read Codes). Additional entries
might be added for co-morbidities such as diabetes or osteoporosis,
or to include social factors such as the needs of carers.
Evidence-based treatment and management
Recommendation 24: People should be managed
according to evidence-based guidelines
Recommendation 13:  All people with COPD should
receive evidence-based treatment using a structured
medicines management approach  
In line with the Chronic Care model,42 treatment of the individual
patient is driven by clinical guidelines – in this case, the NICE 2010
Guidelines.11 The PCRS-UK has adapted the NICE guidelines for use
in primary care (Figure 5)43 and specific details of the use of inhaled
treatments are shown in Figure 6.11 A separate medicines
management guide will be published looking at ways of safe and
cost effective ways of prescribing and using medicines for people
with COPD.
Non-pharmacological interventions
The Consultation document emphasises the following non-
pharmacological interventions:9
1. Smoking cessation
PRIMARY CARE RESPIRATORY JOURNAL
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Figure 4.  Example of a COPD template used for COPD
review.
DATE OF REVIEW READ CODE
FEV1 3390
% PREDICTED FEV1 339S
SMOKING STATUS 137
SMOKING CESSATION ADVICE 8CAL
HEIGHT 229
WEIGHT 8CAL
BODY MASS INDEX (BMI) 22K
Exercise Advice Given 8CA5
Pneumococcal Vaccine Given 6572
Influenza Vaccine Given 65E
BREATHLESSNESS
(MRC SCORE) 173(H-L)
PRODUCTIVE COUGH 171
INHALER TECHNIQUE 663 H/I
Pulmonary Rehabilitation 8FA
COPD self-management  plan 66YI
Depression screening 6891
Acute Exacerbations in last year 66Yf
COPD Admissions 8H2R
PULSE OXIMETRY MEASUREMENT 44YA
PALLIATIVE CARE 2V57C 
NEXT COPD REVIEW 666YL
HYPOXIA?
Oxygen
saturation <92%
at rest in air
FEV1 <30%
predicted
Refer for oxygen
assessment
HOLISTIC CARE
Check social support
(e.g. carers
and benefits)
Treat
co-morbidities
Consider palliative
therapy or secondary
care referral for
resistant symptoms
Refer to specialist
palliative care teams
for end-of-life care
EXACERBATIONS
(Oral steroids/
antibiotics/
hospital
admissions)
Optimise
pharmacologic
therapy
Discuss action plans
including use of standby
oral steroids and
antibiotics
FUNCTIONAL
LIMITATION?
MRC score >3
Optimise
pharmacotherapy
(See algorithm)
Offer pulmonary
rehabilitation
Screen for
anxiety/depression
SYMPTOMS?
Breathlessness
Short-acting
bronchodilators
(β-agonist/antimuscarinic)
for relief of symptoms
Persistent symptoms
See NICE
pharmacotherapy
algorithm
Productive cough
Consider mucolytics
ALL PATIENTS
Smoking cessation advice
Patient education / self management
Assess co-morbidity
ASSESS BMI: Dietary Advice if BMI >25 
Exercise promotion
Pneumococcal vaccination
Annual influenza vaccination
Specialist dietary referral if BMI <20
Figure 5.  Management of Stable COPD in primary care.43
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Recommendation 13 (cont:) A step-up approach to
smoking cessation intervention as part of preventive
management strategies should be taken. 
Smoking status should be checked at every COPD review. Brief
advice and then regular input to aid quitting should be given to
those continuing to struggle against their tobacco dependence.44
2. Oxygen 
Recommendation 14. All people with COPD and
hypoxaemia should be clinically assessed for long-term
oxygen therapy and reviewed at regular intervals, and
existing home oxygen registers should be reviewed.
The provision of home oxygen is a major financial burden on the
NHS (approximately £110 million per annum in England). Oxygen
prescribing for patients with COPD is poorly monitored and may be
inappropriate. Oxygen should only be provided for those who have
demonstrable hypoxia, it is potentially toxic, and patients should be
assessed before it is prescribed. There is no evidence to support the
use of short burst therapy for symptomatic relief of breathlessness.
However, there is strong evidence that long-term oxygen therapy
(> 15 hours per day) for patients with persistent and profound
hypoxia reduces mortality.
In primary care, patients with oxygen saturations persistently
≤ 92% on air when free from an exacerbation should be referred
to oxygen assessment services. Ambulatory oxygen may be
helpful to a minority of patients with exercise desaturation but
should only be prescribed after a specialist assessment. Once
home oxygen is prescribed then the patient should be placed on
a home oxygen register and regularly reviewed.
3. Exercise and  pulmonary rehabilitation
Recommendation 15: All people with COPD should be
advised to undertake moderate exercise according to their
condition. People with functional impairment should be
referred for quality assured pulmonary rehabilitation.
People with COPD, irrespective of severity, become physically
deconditioned due to muscle weakness and loss of cardiovascular
fitness. Exercise is a vital part of COPD treatment.
Those with mild COPD (MRC dyspnoea score 1 or 2) can
increase physical fitness by taking regular exercise in chunks of
variable duration but this should total 150 minutes per week.
Many localities run generic exercise promotion schemes which
may be helpful. Housebound patients (MRC dyspnoea score 5)
may benefit from home-based physiotherapy programmes. 
One of the most cost-effective interventions for patients with
COPD is pulmonary rehabilitation, a multi-disciplinary holistic
intervention aimed at people with COPD who are functionally
impaired but usually not housebound (i.e. MRC dyspnoea score
3 or 4)
Key features of pulmonary rehabilitation are:
• Supervised exercise training with education tailored to promote
self management skills.
• Multidisciplinary input e.g. provided by physiotherapists/
PRIMARY CARE RESPIRATORY JOURNAL
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FEV1 >50%
Breathlessness and
exercise limitation
Exacerbations
or
persistent breathlessness
LAMA
+
LABA + ICS
in a combination
inhaler
Persistent exacerbations
or
breathlessness
Consider therapy
(less strong evidence)
LABA
FEV1 <50%
LAMA
Discontinue SAMA
Offer LAMA in
preference to
regular SAMA
four times a day
LABA + ICS
in a combination
inhaler
Consider LABA +
LAMA if ICS
declined or not
tolerated
LAMA
Discontinue SAMA
Offer LAMA in
preference to
regular SAMA
four times a day
LABA + ICS
in a combination
inhaler
Consider LABA + LAMA
if ICS declined or
not toelrated
SABA or SAMA as required*
Other therapy
(strong evidence)
Figure 6. Inhaled pharmacotheray algorithm (adapted from NICE with permission11).
SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid
*SABA (as required) may continue at all stages
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doctors/ nurses/nutritionist/psychologist
• It can be provided in hospitals or in the community
• A programme is typically run for 6-12 weeks.
There is strong evidence that pulmonary rehabilitation can
improve exercise tolerance, quality of life and activities of daily
living. It has been shown to reduce healthcare utilisation and is
very cost effective. Unfortunately, pulmonary rehabilitation has
not been universally available in England, and the Strategy
Consultation document9 encourages its wider availability.
Publication of more detailed guidance regarding the specification
of a high quality pulmonary rehabilitation service is being
planned.
4. Reducing psychological stress
Many patients with COPD have depression and anxiety; 25% are
clinically depressed and the incidence of depression may be higher
in patients with functional limitation. It is important to diagnose
these patients.
The Strategy Consultation document9 and the NICE
guidelines11 advise that patients should have access to a range of
interventions including cognitive behavioural therapy and
pharmacological treatments. It is recommended that a clinical
psychologist be included in the multidisciplinary pulmonary
rehabilitation team.
Self-management and self-care
Hilary Pinnock
People with COPD live with their slowly deteriorating condition over
many decades. Of necessity, they and their families develop self-care
strategies to deal as best they can with the tobacco dependence,
increasing disability, unpredictable exacerbations, complex
medication regimes, co-morbidity and social isolation. The
Consultation on a Strategy for Services for COPD in England
emphasises the key role of all healthcare professionals in providing
not only clinically focused self-management advice, but also holistic
support to enable individual patients to self-care more effectively.9
Information for self-care
Recommendation 11: Good-quality information should be
provided at diagnosis and delivered in a format that any
person can understand. 
Effective self-care is underpinned by accurate and accessible
information, tailored to the individual’s disability, relevant to their
personal circumstances and sensitive to their preferences for
knowledge and autonomy.  Key topics identified by people with
COPD and their carers include education about the disease,
management of breathlessness, pharmacological treatments,
management of exacerbations, psychological support, and guidance
on welfare benefits.9 Education should start at the point of diagnosis
and be extended appropriately as the disease evolves.
Useful sources of information include: 
• the British Lung Foundation website (http://www.lunguk.org)
includes written and video resources on COPD.45
• NHS Choices (http://www.nhs.uk),46 for information on healthy
lifestyles, specific diseases and NHS services. An Information
Prescription is an NHS initiative which aims to collate
information specifically tailored to the individual patients’ needs.
Although intended to be compiled in discussion with a clinician,
an online version enables a patient to choose the topics and
services in which they are interested.47 
Managing their condition
Recommendation 16: People with COPD should be
encouraged to learn how to help manage their condition
themselves…
1. Lifestyle choices
Smoking status should be checked at every COPD review, and
brief advice given to those who continue to smoke.44 Useful
guidance is available from http://www.theipcrg.org/smoking/
index.php. 
Increasing breathlessness, reduced activity, and consequent
deconditioning are not the only barriers to remaining active:
practical solutions may be needed to overcome practical
problems (e.g. top floor flats with no lifts). Patients should be
encouraged to set their own goals as a target for improvement.
2. Using medication
Patients need information about their treatment, including how
and when to take it, and discussion on any safety concerns.
Reviewing inhaler technique annually is only helpful if action is
taken to address problems – changing to an alternative device
may be more effective than repeatedly correcting poor
technique. 
Self-management of exacerbations
Self-management education – including action plans about when
and how to adjust and/or start medication in case of an
exacerbation – reduces hospital admissions and significantly
improves breathlessness and respiratory-related quality of life.48
• Recognising deterioration: There are no physiological
measures which predict exacerbations reliably, so patients are
asked to monitor their symptoms (increased breathlessness,
and increased quantity and purulence of sputum). Tools such
as sputum colour charts may help patients differentiate
exacerbations from ‘bad days’ with COPD. 
• Taking action: Patients vary in the degree of autonomy that
they wish to accept. Most will be happy to keep emergency
supplies of steroids and antibiotics, though some will prefer
to talk with a clinician before commencing treatment (see
Figure 7). When to seek urgent advice is equally important.  
Self-management plans should be reviewed regularly and
revised as COPD progresses. Ongoing trials are testing whether
tele-monitoring can reduce admissions by supporting self-
management.49 A Met Office initiative uses data about prevalent
viruses combined with forecast cold weather to predict high risk
of admissions so that patients can be prepared.50
PRIMARY CARE RESPIRATORY JOURNAL
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Support for self-care
Recommendation 16 (cont): …and how to have
positive interactions with healthcare professionals and
others about their condition.
People with respiratory long-term conditions value the support of
a trusted clinician,51 and healthcare services need to ensure
flexible access to professional advice.52 A face-to-face
consultation may be required to deal with an exacerbation; on
other occasions a brief telephone call or e-mail communication
may suffice to answer a query.51 NHS choices includes web-based
resources to support self-care.53
Recommendation 16 (cont): They should also be
encouraged to engage with others who have COPD in
order to promote exchanges of information, support and
advice.
Peer support is helpful, and many patients value the on-going
support of their local BreatheEasy group.54 ‘Expert patient’
courses teach generic skills of relevance to people with COPD.55
Personalised care plans 
It has been proposed that all people with long-term conditions,
including COPD, should have a Personalised Care Plan (PCP).56
PCPs are owned by the patient, reflect their goals, and are
tailored to individual circumstances. A clinical action plan
advising on emergency management is likely to be a core
component of a PCP, but in complex situations plans would also
include details of care services, social needs and, if relevant,
advanced care planning. Whether or not PCPs for COPD patients
provide additional benefits over self-management or action plans
is unknown.  
Management of acute exacerbations
Kevin Gruffydd-Jones and Sarah-Jane Peffers
Definition
An acute exacerbation is defined by the Strategy Consultation
document as a sustained worsening of an individual’s symptoms
from their usual stable state which is rapid in onset.9
COPD exacerbations are a burden on the individual patient
and on health services throughout the world, and are associated
with faster disease progression, worsening quality of life and
increased mortality.
COPD was the second highest cause of hospital admissions in
2007/2008,2 with 15% of patients dying within three months of
admission.57 
The Consultation document makes several recommendations
regarding the management of acute exacerbations of COPD,9
some of which are relevant to primary care:
PRIMARY CARE RESPIRATORY JOURNAL
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Figure 7.  The Plymouth self-management plan (reproduced with the permission of Dr Rupert Jones).
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Recommendation 17: The quality of the identification
and management of exacerbations should be improved
and all people with COPD who have an exacerbation
should be reviewed afterwards to ensure that their
treatment remains optimal and relapses are reduced to a
minimum.
Recommendations 18: All people with COPD in respiratory
failure should be issued with oxygen alert cards, and
ambulance staff should be able to recognise and respond
appropriately to respiratory failure in COPD.
Recommendation 19: People with COPD should receive a
specialist respiratory review when acute episodes have
required referral to hospital. They should be assessed for
management by early discharge schemes, or by a structured
hospital admission, to ensure that length of stay and
subsequent readmission are minimised. 
Recommendation 20: All people with acute respiratory
failure should be identified and investigated promptly and
offered treatment with non-invasive ventilation (NIV) with
access to mechanical ventilation, if required. 
The need for early recognition of exacerbations
Whilst most COPD exacerbations are treated in the community,
about 50% of patients with an acute COPD exacerbation do not
present to a healthcare professional.58 Detailed guidance for
treatment is provided in the NICE guidelines,11 and the earlier
treatment is started the less chance there is of hospital admission.59
Provision of individualised self-management strategies  including
action plans which help the patient to identify and treat early signs
of an exacerbation can reduce hospital admissions60 (see above). 
Assessment
Assessment should include:
• Level of consciousness
• Assessment of degree of breathlessness, (respiratory rate, use of
accessory muscles)
• Degree of hypoxaemia (presence of cyanosis, oxygen saturation
below 92%)
• History and examination to exclude alternative diagnoses (e.g.
pneumonia, pulmonary embolus) and to assess co-morbidities. 
• Ability to cope at home during the course of an exacerbation
(including degree of carer support available)
Treatment
1. Patient self-management
Many patients will have started management themselves by use of
stand-by antibiotics for cough with purulent sputum, increased use
of short-acting bronchodilator, and/or use of standby oral steroids
and breathing exercises. The Strategy recommends that patients
inform their usual healthcare professional within two days of
starting their exacerbation therapy (see below). 
2. Management in primary care
After initial assessment, treatment should be initiated in line with
national and local guidance (see Table 4). 
Various factors are considered when deciding whether to treat the
patient at home or in hospital (see Table 5). This may vary according
to available home care support (e.g. “hospital at home” services). 
Review 
Where patients have been treated for an exacerbation in the
community, the patient should be reviewed at least at the end of the
initial treatment period (e.g. after one week of oral antibiotics
and/or oral steroids) or sooner if the clinical condition warrants this.
Further review at six weeks should include optimisation of
pharmacological and non-pharmacological therapy and
reinforcement of self-management education (see Figure 8).
Hospital admission
The detailed recommendations regarding in-patient management
are beyond the scope of this primary care-focussed supplement, but
they include:
• Prompt access to non-invasive ventilation (NIV) and/or
mechanical ventilation for patients in acute respiratory failure.
• Review during admission by a member of the specialist
respiratory team.
• Review of management of the acute condition and of co-
morbid conditions 
Increased • Increase frequency and dose of  short 
breathlessness acting bronchodilation (e.g salbutamol 
400-800mcg 3-hrly). Deliver via a 
hand-held inhaler (including a spacer 
device if appropriate), or nebuliser if unable 
to use a spacer.
• Commence oral steroids if symptoms 
persist (30mg prednisolone for 7-10 days)
Purulent sputum • Start course of broad spectrum antibiotics. 
• Encourage Active Cycle of Breathing 
Technique (ACBT) to help expectorate 
sputum.
• Consider using the mucolytic erdosteine for 
up to 10 days.
Measure Oxygen Oxygen saturations < 92% warrant the 
Saturations by administration of 24%-28% oxygen
Pulse Oximetry at 2-4l/minute  delivered via a Venturi mask .
The aim is to maintain oxygen  saturation at 
between 88%-92%.*
*Many COPD patients rely on a hypoxic drive to maintain adequate ventilation. 
High oxygen delivery rates and concentrations can suppress this drive and 
precipitate hypercapnic respiratory failure. It is therefore recommended that 
COPD patients at risk of developing hypercapnia (i.e. those with previous 
hypercapnic respiratory failure) carry oxygen alert cards and that ambulance 
staff are aware of the need to control oxygen flow rates if a COPD patient is 
transferred to hospital.61
Table 4. Initial treatment of symptoms of an acute
exacerbation of COPD in the community.
Copyright PCRS-UK - reproduction prohibited
http://www.thepcrj.org
Co
py
rig
ht 
Pr
im
ary
 C
are
 R
es
pir
ato
ry 
So
cie
ty 
UK
 
Re
pro
du
cti
on
 pr
oh
ibi
t d
Summary of the Consultation on a Strategy for Services for COPD in England
S13PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
• Review of discharge arrangements including the requirement for
continuing care in the community (including the provision of
oxygen post admission, rehabilitation programmes, and
psychosocial support).
• Review of chronic management including self-management
advice.
Review post-discharge
Thirty-three percent of patients are readmitted to hospital within
three months of an acute exacerbation of COPD.57 There is evidence
that discharge procedures are inadequate and that some patients
are left socially isolated and depressed.62 The UK National COPD
Audit of 200857 showed a median time to readmission of 38 days,
with 25% of patients being readmitted within 20 days, thus
suggesting that review should be carried out within three weeks of
hospital discharge (see Figure 8). The Consultation document’s
recommendation of post-discharge review within six weeks9 may
therefore be too lenient, and this may need to be reviewed before
publication of the final Strategy document.
Admission avoidance and early discharge schemes
There are a variety of models of care available to minimise the
impact of acute exacerbations of COPD.63 These include validated
early assisted discharge schemes from hospital, and “hospital at
home” admission avoidance schemes provided by specialist
community teams or hospital outreach teams. These have the
potential to reduce hospital admission rates and inpatient stays.
Such schemes are preferred by people with COPD and have proved
to be a cheaper option than usual care. Other novel methods of
care, such as telemedicine, could have the potential to identify
exacerbations at an early stage, trigger early interventions and
reduce the risk of hospital admission.49
End-of-life care
Patrick White and Jane Scullion
Recommendation 21: There should be improved access to
high-quality end-of-life care services that ensure equity in
care provision for people with severe COPD, regardless of
setting.
Recommendation 22: Access to information and
appropriate support should be available to carers and those
who are bereaved.
For people diagnosed with COPD it is inevitable that whilst they may
or may not die from their condition they will certainly die with it.
COPD is a chronic and progressive disease in which treatments are
aimed mainly at improving symptoms but have little impact on
disease progression. The treatment of advanced COPD is therefore
essentially palliative. It can be seen to fit the basic tenets of palliative
care although there are also specific end-of-life issues.
Recommendations 21 and 22 link well with guidelines for end-of-
life-care of people with non-malignant diseases.9,64 They emphasise
the importance of access both to high quality end-of-life-care and to
appropriate information and support for carers. The
recommendations come with three associated action points (Actions
30-32) which propose piloting markers of a prognostic indicator,
publishing core workforce skill requirements, and piloting and
evaluating an end-of-life care pathway.  
The recommendations and the actions highlight the
challenge facing clinicians working with patients with advanced
Figure 8.  Features of a post-exacerbation review
(adapted from the GOLD report31 by Dr Gruffydd-Jones).
• Optimise acute treatment including pharmacotherapy,
provision of oxygen and pulmonary rehabilitation
where appropriate.
• Optimise psychosocial support.
• Discuss/reinforce self-management education
including the use of self-management plans.
• Consider discussion of possible palliative care
(including end-of life issues if appropriate) including
action to be taken if further exacerbations.
• Optimise chronic care to prevent exacerbations. 
Factor Treat at home Treat in hospital 
Able to cope at home Yes No
Breathlessness Mild Severe
General condition Good Poor/deteriorating
Level of activity Good Poor/confined to bed
Cyanosis No Yes
Worsening peripheral oedema No Yes
Level of consciousness Normal Impaired
Already receiving LTOT* No Yes
Social circumstances Good Living alone/not coping
Acute confusion No Yes
Rapid rate of onset No Yes
Significant co-morbidity No Yes
(particularly cardiac disease 
and insulin-dependent diabetes)
SaO2 < 90% No Yes
Changes on chest radiograph No Present
Arterial pH level > 7.35 < 7.35
Arterial PaO2 > 7 kPa < 7 kPa
* LTOT: long-term oxygen therapy
Table 5. Factors to consider when considering where to
treat a patient with acute COPD (adapted from NICE
with permission11).
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COPD. It is difficult to identify patients who are dying from
COPD. For those who are identified, there is no recognised
pathway of care, although the document9 includes the end-of-
life care pathway of the Department of Health End of Life Care
Strategy.64 An additional challenge concerns the palliation of
symptoms, predominantly breathlessness (see Table 6).65
Breathlessness is the most important problem to people with
advanced COPD and in many patients palliation of breathlessness
should be addressed even before they can be defined as having
reached the terminal phase of the disease.66 Whether palliation of
breathlessness should be considered alongside end-of-life-care of
COPD or should be considered in the mainstream management
of the disease is an issue for further discussion. Palliation of
breathlessness in advanced COPD will likely be confused with
end-of-life-care, and it will not be easy for clinicians to consider
it until they have started to think in terms of end-of-life-care.67 As
the palliation of breathlessness becomes more widely understood
in COPD it is likely to be seen and treated separately. 
Symptom control in advanced COPD requires an expertise
which is often lacking in traditional care of the disease.68 COPD
management is usually reactive and aimed at crisis intervention,
whereas a palliative care approach should be more proactive. In
order to manage symptoms, it is first necessary to look at
patients’ understanding of their disease, what they believe
caused it and what they anticipate can be done about it. If we
manage to address patients’ perceptions of their condition we
can more adequately assess general well-being and the likely
effectiveness of treatments. It may be necessary to explore
beyond the impact of dyspnoea and declining lung function. The
role of social and emotional issues, the experience of panic
attacks, and the fear of dying may be critical to wellbeing in
advanced COPD. In this respect it is good to see the needs of
carers addressed in the Strategy Consultation document.9 COPD
is a disease with social ramifications beyond the individual
affected especially in its advanced stages.
The Consultation document acknowledges the difficulty
clinicians face in defining prognosis in advanced COPD and the
impact that this is likely to have in determining when patients
have reached the end stage of the disease.9 The document is
positive about prognosis in referring to the BODE index33 as a tool
for predicting mortality – though this is poorly supported by the
Gold Standards Framework69 and by evidence provided by
systematic reviews of end-of-life-care of COPD.70-72 BODE is not
definitive in predicting mortality in the context of end-of-life care.
Even using the most severe category of the BODE index, 70% of
subjects will still be alive at two years so it does not enable us to
predict when patients will die. 
The best indices of survival in advanced disease based on
current evidence are more likely to be the generic characteristics
of proximity of death – such as progressive loss of function and
weight, and progressive symptoms. For a person with COPD we
would therefore expect a poor prognosis in someone with severe
airflow obstruction (MRC Dyspnoea score of 5) on long-term
oxygen therapy (LTOT), with weight loss and increasing
hospitalisations. These practical markers may incline us to initiate
the discussion about end-of-life with the patient and their carers.
The End-of-Life Care chapter of the COPD Strategy
Consultation document is welcome, because it highlights a
problematic area of COPD care for clinicians, addressing many as
yet unanswered questions, and it indicates the need for further
key research in this important but largely uncharted area. 
Implementing the Strategy for COPD
Services in England, measuring outcomes,
and commissioning care
Rupert Jones 
COPD Strategy objectives 
The key objectives of the Strategy are:
• Prevention and early identification
• Good quality early diagnosis
• High quality care and support following diagnosis 
• Improving access to end-of-life services 
The role of the Strategy is to ensure that organisations which
provide respiratory services have a framework which defines the
standards for those services. The Consultation on the Strategy for
Services for COPD in England9 sets out standards for services,
including clinical standards set by NICE,11 and how these
standards are to be implemented. 
The background to implementation
The Strategy Consultation document was published as a draft
version in February 2010,9 but the actual Strategy and its
implementation plan has yet to be finalised and launched.
The White paper ‘Equity and excellence: Liberating the NHS’10
proposes far-reaching changes to the UK NHS including
commissioning by GPs and phasing out of Strategic Health
Authorities (SHAs) and Primary Care Trusts (PCTs). Ensuring
quality of services remains an important element of government
policy, but with new emphasis on measuring outcomes, rather
than process, especially Patient-Reported Outcome Measures
(PROMS) and patient experience. There will be an increased role
for patients in designing, delivering and monitoring the service as
well as strengthening patient choice. Proposals are made to
reform long-term prevention strategies in partnership with other
fields such as social care and public health, all to be delivered
with reduced management costs.
The NHS will have to save £20 billion over the next three
• Breathlessness
• Fatigue
• Pain
• Insomnia
• Cough
• Anxiety and depression
• Fear and panic
• Weight loss / Cachexia
Table 6. Symptoms often experienced by patients with
advanced COPD (Reproduced with permission from the
Department of Health64).
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years (a saving of approximately £1,000 for every person in
England every year). Implementing all of the recommendations in
the Strategy Consultation document9 may increase healthcare
costs in the short term but reduce them in the long term. Direct
savings can be made by reducing inappropriate drug and oxygen
therapy while savings are anticipated through strategies to reduce
exacerbations, admissions and disease progression such as
smoking cessation, rehabilitation and drug treatments. The
impact assessment published in February 2010 has predicted that
over 10 years the net benefit of implementing the Strategy to the
NHS will be £1,075m (range £235-3,407m).73 
Implementation Mechanisms
The implementation of the strategy will occur at different levels.
1. Clinical networks
Regional SHA respiratory clinical leads have been appointed to
establish a network of managers and clinicians to oversee the service
development. How each region operates will vary in practice, but
they will seek to bring together services in primary, secondary and
intermediate care as well as private providers. Independent third
sector providers are expected to increase in number and will need to
be assessed in conjunction with existing NHS services. As PCTs are
phased out, the services they currently provide will need to be re-
aligned either to be under the aegis of a GP consortium, hospital
trust or becoming an independent social enterprise company.  
Particular attention will be paid to the key priorities for
implementation from the NICE COPD guideline11: 
• Diagnose COPD and confirm airflow obstruction by post-
bronchodilator spirometry 
• Stop smoking 
• Promote effective inhaled therapy
• Provide pulmonary rehabilitation for all who need it, including
those who have had a recent hospitalisation for an  acute
exacerbation 
• Use non-invasive ventilation (NIV) for persistent hypercapnic
ventilatory failure during exacerbations not responding to
medical therapy
• Manage exacerbations
• Ensure multi-disciplinary working
The clinical leads will assess services in terms of process and
outcomes;
Process: 
What services are currently in place? 
What are the gaps in provision including accessibility for services
such as spirometry, structured care, pulmonary rehabilitation and
NIV?
Outcomes: 
The quality of services will be measured using common
assessment methods (see Metrics section below). Services which
provide an efficient and effective service to improve patient-
centred outcomes, reduce costs and disease progression, will be
identified and emulated. Standards are being set for the quality
of the service to guide commissioners and those assessing the
service; many standards are defined in the Strategy Consultation
document,9 and others – such as the programme for
Physiological Measurement standards – are ongoing.
2. Metrics
There is an ongoing stream of work to define best outcome
measures in a range of areas including the following:
(i) Quality of diagnostic services: 
Assess diagnostic standard spirometry provision as defined by
the Consultation document9 and subsequent guidance. Clinical
leads will assess the quality of services irrespective of where they
are delivered. 
(ii) Data recording:
Data recording in primary care and in hospital services will be
checked, including NICE-approved items such as the MRC
dyspnoea scale and exacerbation frequency. NICE is now revising
the Quality Outcomes Framework (QOF) markers for COPD.
(iii) Structured care:
The recording of patient reviews at recommended intervals
depending on disease severity, and items such as offering
smoking cessation to current smokers and pulmonary
rehabilitation for those with MRC dyspnoea score of 3 or above
will be required. Another marker is the documented provision of
care plans including self-management advice and reviews post-
exacerbation/admission.
(iv) In-patient care:
The metrics in secondary care may well follow those used in the
RCP audits74,75 including admission rates and duration, the
proportion of in-patients managed by a chest specialist,
readmission rates within three months, and mortality (both in-
patient and within three months post-admission). The 24 hour
availability and patient experience of NIV is a likely marker.
(v) Accessible, high quality local services:
Availability of services such as pulmonary rehabilitation and
oxygen assessment services will be important. Suitable metrics
may include the number of patients prescribed oxygen, the
proportion who had a formal assessment, and the proportion on
short burst oxygen.
3. Commissioners
Commissioning of services will be overseen by a new national
independent board. Regional respiratory clinical leads will have a role
in monitoring services and establishing clinical networks to promote
better service integration and delivery of respiratory services. The
DOH will be issuing clear guidance to commissioners in a document
anticipated at the end of 2010.
GP consortia will have responsibility for commissioning
services for people with COPD. GP consortia will have a
nationally-set budget and there will be a personal health budget
for people with long-term conditions to ensure that those
providing for these patients have the appropriate resources. 
Summary
The UK NHS can no longer afford to ignore COPD. Implementing the
recommendations in the Consultation on a Strategy for Services for
COPD in England should reduce the inordinate and growing costs of
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COPD, both human and financial. New systems of commissioning,
provision and monitoring of services in a rapidly changing NHS are
outlined. A new unified approach to provision of high quality and
uniform COPD services is being developed. To deliver better services,
primary care will have to work more closely with other GPs in
consortia and with clinical networks. It is hoped that incentives such
as QOF payments and GP commissioning will be used to drive
increased quality of care. There will be a new emphasis on
‘outcomes’ rather than ‘process’, particularly patient-related
outcomes and patient experience. 
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